Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| CHANDRA, GYAN | 1 | 71.3% | +27.4% |
| JOHNSON, TIRONE DEREK | 1 | — | — |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| HAM, JIEUN | 1 | 50.0% | +62.5% |
| NATARAJAN, MEERA | 1 | 62.3% | +17.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283385 | MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING | JOHNSON, TIRONE DEREK | 34d |
| 18164649 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | NATARAJAN, MEERA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18490804 | MULTISPECIFIC NKp46 BINDING PROTEINS | HUYNH, PHUONG N | 44d overdue |
| 18331966 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | PUTTLITZ, KARL J | 15d overdue |
| 18285668 | IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS | CHANDRA, GYAN | — |
| 18038723 | TREATMENT OF CANCER | HAM, JIEUN | — |
| 18164649 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | NATARAJAN, MEERA | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1641 | 1 |
| 1674 | 1 |
| 1675 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18490804 | MULTISPECIFIC NKp46 BINDING PROTEINS | HUYNH, PHUONG N | 1641 | §112Other | Non-Final OA | 44d overdue | Pending | Oct 20, 2023 |
| 18285668 | IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS | CHANDRA, GYAN | 1674 | §112 | Final Rejection | — | Pending | Oct 05, 2023 |
| 18283385 | MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING | JOHNSON, TIRONE DEREK | 1675 | §103§112 | Non-Final OA | 34d | Pending | Sep 21, 2023 |
| 18331966 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | PUTTLITZ, KARL J | 1646 | §103DP | Non-Final OA | 15d overdue | Pending | Jun 09, 2023 |
| 18038723 | TREATMENT OF CANCER | HAM, JIEUN | 1643 | §102§112DPOther | Non-Final OA | — | Pending | May 25, 2023 |
| 18164649 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | NATARAJAN, MEERA | 1643 | §102§103§112 | Non-Final OA | — | Pending | Feb 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial